GEROTHERAPEUTIX is actively expanding a proprietary database of newly generated MitoXcel™ geropeptide candidates. Each candidate is evaluated through a rigorous complement of proprietary in vitro assays to assess potency across both Mechanism 1 and Mechanism 2.
Through an iterative learning process, MitoXcelAI™ – the platform’s proprietary artificial intelligence engine – analyzes this growing dataset to train and refine predictive algorithms. With each experimental cycle, the system strengthens and sharpens the design rules that define MitoXcel™ Technology.
This continuous feedback loop enhances the precision and performance of the platform, ensuring its ongoing evolution as a best‑in‑class, information‑engineered solution for generating novel geropeptides designed to combat age‑related decline—while our expanding dataset and newly added platform members drive a steady stream of fresh intellectual property filings. Our growing pipeline of proprietary MitoXcel™ geropeptides include clinical candidates with just Mechanism 1 activity, with just Mechanism 2 activity, and with both Mechanism 1 and 2 activity.
